213 Users Online
Biobetters Market Segmented by erythropoietin biobetters, G-CSF biobetters, interferon biobetter, insulin biobetters, monoclonal antibodies biobetters, antihemophilic factors Drugs Class as diabetes, cancer, renal disease, neurodegenerative disease, genetic disorders Indications by subcutaneous and intravenous Route of Administration
Biobetters Market witnessed a CAGR of 7.3% between 2014 and 2021. The global Biobetters Market is expected to witness a steady 8.3% CAGR between 2022 and 2029. In 2022, the global Biobetters Market size was US$ 55,752.3 million, which is projected to reach US$ 99,262.5 million by the year 2029.
| Attribute | Key Insights |
|---|---|
|
Biobetters Market Size (2022) |
US$ 55,752.3 Mn |
|
Projected Market Value (2029) |
US$ 99,262.5 Mn |
|
Global Market Growth Rate (2022-2029) |
8.6% CAGR |
|
Share in parent market |
404.2% |
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Biobetters, also known as biosuperiors, are recombinant protein drugs from an identical class as a present set of biopharmaceuticals is not similar to the source. It is neither a wholly novel medicine nor a generic version of an old drug. It is a biological product designed to increase clinical efficacy while also improving tolerance and lowering dosing/administration frequency. The Biobetters Market is expected to witness a CAGR of 8.6% due to the advantages of Biobetters such as superior therapeutic efficacy, lesser side effects, easier and less expensive production methods, non-patent and market exclusivity, longer product half-life, lower dosage frequency, and the availability of high investment prospects.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionHigh Efficacy and Few Side Effects
Biobetters are designed to be enhanced variants of existing biologics in terms of therapeutic benefit, dose frequency, side effects, and so on. Furthermore, they are intended to be more effective than already available biologics. Furthermore, due to the low dosing frequency, patients usually complete their entire treatment cycle. Hence, the Biobetters market is expected to grow significantly going forward.
Simple and Less Expensive Manufacturing Process
The manufacturing procedure of biobetters is identical to that of biologics; however, modern technologies such as pegylation, albumin replacement, and so on are used as well. Several manufacturers are effectively employing these techniques in the production of different biobetters. Biobetters have a lower development cost and take roughly 10 years to develop, whereas biologics demand a greater investment and take approximately 15 years to develop. While biosimilars have a cost of development that is almost half that of biobetters, their therapeutic effectiveness is far superior.
“Increasing Research Activities”
Manufacturers and investors in the biobetters industry are continuously focused on developing better formulations. Biopharmaceuticals are looking for novel techniques to evaluate complicated structures in order to build better biobetters. An array of biophysical and biochemical approaches have arisen in recent years in the evolution of the biobetters industry, offering a significant push to its expansion.
Increased Investment in Developing Therapeutic Agents
Increasing investment in developing therapeutic agents with enhanced effectiveness and safety profiles for cancers and autoimmune illnesses has influenced the biobetters market's growth dynamics. There have been considerable attempts in recent years to reduce the economic impact of chronic illnesses. The increasing investment in developing new drugs is likely to fuel market growth in the near future.
“High Investments Required for R&D Activities”
Developing novel medicinal drugs necessitates large investments in the research and development process, which limits the market growth. However, since the Covid-19 virus outbreak, there has been a huge rise in R&D spending for developing novel biobetters. Apart from that, rising biosimilar competition is also restricting the market growth.
Sales Team
Client Partner
“Increase in the investment for developing novel biobetters”
There has been a significant increase in R&D investment for developing novel biobetters since the Covid-19 virus outbreak. Manufacturers and investors in the biobetter industry are constantly working to improve formulations, and many novel medications are in the pipeline or clinical trials.
The Biobetters market is highly competitive and consists of significant major players, that dominate the market. The market players are focusing on mergers and strategic alliances as the industry is in the growth phase.
| Attribute | Details |
|---|---|
|
Forecast Period |
2022-2029 |
|
Historical Data Available for |
2014-2021 |
|
Market Analysis |
US$ Mn/Bn for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
By Distribution Channel |
|
Key Companies Profiled |
|
|
Customization & Pricing |
Available upon Request |
Biobetters Market by By Distribution Channel
Biobetters Market By Molecule Type
Biobetters Market by Disease Indication
Biobetters Market by Region
In 2022, the Biobetters Market stands at USD 55,752.3million, and it is expected to reach USD 99,262.5 million by 2029 at a CAGR of 8.6%.
Biobetters Market exhibited a 7.3% CAGR between 2014 and 2021.
High investments and rising biosimilar competition are the key restraints in the Biobetters Market.
High Efficacy and Few Side Effects of Biobetters are the key factors driving the growth of the market.
F.Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, SERVIER, and Porton Biopharma Limited are among the top players in the market.
